United Therapeutics Corporation
UTHRUnited Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Drugs in Pipeline
28
Phase 3 Programs
11
Upcoming Catalysts
2
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How UTHR's past catalysts played out
Tadalafil
Pulmonary Hypertension
Treprostinil Diolamine
Pulmonary Arterial Hypertension
Ralinepag
Pulmonary Arterial Hypertension
UT-15
Pulmonary Hypertension
oral treprostinil
PAH
UT-15C SR
Pulmonary Hypertension
UT-15C (treprostinil diolamine)
Pulmonary Arterial Hypertension
Dinutuximab
Small Cell Lung Cancer
Oral treprostinil (UT-15C) Sustained Release Tablets
Pulmonary Hypertension
treprostinil diethanolamine
Pulmonary Arterial Hypertension
Inhaled Treprostinil
Progressive Pulmonary Fibrosis
Hyperpolarized 129Xenon gas
Pulmonary Vascular Disease
10 GE Xenokidney
ESRD (End-Stage Renal Disease)
Treprostinil
Pulmonary Arterial Hypertension
Qutenza (8% capsaicin)
Pulmonary Hypertension
UT-15C
Pulmonary Hypertension
Tyvaso Inhalation Solution
Pulmonary Arterial Hypertension
UB-421
HIV-1 Infection
UB-421(25 mg/kg) Q2W
HIV-1 Infection
0.5% Ivermectin lotion
Pediculosis Capitis
Irinotecan Hydrochloride
Ganglioneuroblastoma
GGTA1 KO Thymokidney
ESRD (End-Stage Renal Disease)
APD811
Pulmonary Arterial Hypertension
Qutenza
Pulmonary Hypertension
treprostinil dienthanolmine sustained release
Critical Limb Ischemia
Inhaled Treprostinil (Tyvaso Nebulizer)
COPD (Chronic Obstructive Pulmonary Disease)
ch14.18 -NCI
Neuroblastoma
Universal Donor (UD) TGFβi NK Cells
Neuroblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tadalafil | Phase 3 | Pulmonary Hypertension | - | - |
Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Ralinepag | Phase 3 | Pulmonary Arterial Hypertension | - | - |
UT-15 | Phase 3 | Pulmonary Hypertension | - | - |
oral treprostinil | Phase 3 | PAH | - | - |
UT-15C SR | Phase 3 | Pulmonary Hypertension | - | - |
UT-15C (treprostinil diolamine) | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Dinutuximab | Phase 3 | Small Cell Lung Cancer | - | - |
Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension | - | - |
treprostinil diethanolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Inhaled Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | - | - |
Hyperpolarized 129Xenon gas | Phase 2 | Pulmonary Vascular Disease | - | - |
10 GE Xenokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
Treprostinil | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Qutenza (8% capsaicin) | Phase 2 | Pulmonary Hypertension | - | - |
UT-15C | Phase 2 | Pulmonary Hypertension | - | - |
Tyvaso Inhalation Solution | Phase 2 | Pulmonary Arterial Hypertension | - | - |
UB-421 | Phase 2 | HIV-1 Infection | - | - |
UB-421(25 mg/kg) Q2W | Phase 2 | HIV-1 Infection | - | - |
0.5% Ivermectin lotion | Phase 2 | Pediculosis Capitis | - | - |
Irinotecan Hydrochloride | Phase 2 | Ganglioneuroblastoma | - | - |
GGTA1 KO Thymokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
APD811 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Qutenza | Phase 2 | Pulmonary Hypertension | - | - |
treprostinil dienthanolmine sustained release | Phase 2 | Critical Limb Ischemia | - | - |
Inhaled Treprostinil (Tyvaso Nebulizer) | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | - | - |
ch14.18 -NCI | Phase 2 | Neuroblastoma | - | - |
Universal Donor (UD) TGFβi NK Cells | Phase 2 | Neuroblastoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in United Therapeutics Corporation's drug pipeline?→
CatalystAlert tracks 28 drug candidates in United Therapeutics Corporation's (UTHR) pipeline across Phase 3, Phase 2. Its lead program is Tadalafil (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is United Therapeutics Corporation's next FDA catalyst?→
United Therapeutics Corporation's (UTHR) next tracked catalyst is a Phase 2 expected July 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UTHR biotech catalysts?→
Add UTHR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow United Therapeutics Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.